Cardio Diagnostics (CDIO) vs Enlivex (ENLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Enlivex is the larger company by market cap ($5.5 million vs $5.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CDIO | ENLV |
|---|---|---|
| Share price | $1.86 | $0.277 |
| Market cap | $5.50M | $5.51M |
| 1-day change | -5.58% | -10.85% |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-2.91 | $494.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.91 | $27.15 |
| 52-week low | $0.97 | $0.255 |
| Distance from 52-week high | -76.49% | -98.98% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +28780.87% |
| Average volume | 56.01K | 945.30K |
| Shares outstanding | 2.96M | 19.91M |
| Employees | 15 | 34 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cardio Diagnostics
CDIO stock →Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
Healthcare · Biotechnology · 15 employees
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Healthcare · Biotechnology · 34 employees
CDIO vs ENLV FAQ
Which is bigger, Cardio Diagnostics or Enlivex?
Enlivex (ENLV) is larger, with a market capitalization of $5.51M compared with $5.50M for Cardio Diagnostics (CDIO).
Are Cardio Diagnostics and Enlivex in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.